Abry Partners, a Boston-based private equity firm, and BHMS Investments, LP, a Connecticut-based private equity firm, have completed the sale of Innovisk to Ryan Specialty , a leading international ...

Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Reports Q3 revenue $2.77B, consensus $2.72B. “The third quarter marked another period of strong progress, with continued revenue growth ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex beat third-quarter expectations late Monday, but an analyst says Vertex stock needs more "to drive another leg of stock upside." ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Amazon.com closed up more than +6% after forecasting Q4 operating income above consensus. Also, chip stocks rallied on Friday, led by a +7% jump in Intel after it reported better-than-expected Q3 ...

Strategic collaborations above 60,000 feet unlocks new potential for traffic and climate management, earth observation and imaging, methane, storm, and wildfire detection, and more ROSWELL, ...